Top of this page
Skip navigation, go straight to the content

Continuing our growth path in 2016

  • Posted by

    • The growth of UCB’s main products is driving our continued growth in 2016,
    • topline results from our clinical research programs show promise in the treatment of osteoporosis and
    • we now have 9 attractive projects in our early pipeline.
    These are among the highlights of our company’s three months interim report of 2016 which also confirms the financial outlook for the year.

    Our report shows revenue for the first three months 2016 of €991 million, an increase of 11% (or 9% at constant exchange rates). Net sales of our main products are up 15%, totaling €714 million in net sales.

    We do expect continued growth this year with 2016 revenue reaching approximately €4.0 billion - €4.1 billion. Recurring Earnings before interest, taxes, depreciation and amortization (rEBITDA) are expected to increase to approximately €970 million - €1 010 million. REBITDA is considered as an indicator of a company’s underlying earnings performance and, in this case, highlights UCB’s healthy growth. Core earnings per share for 2016 are expected in the range of €2.90 - €3.20.

    Our product portfolio available to patients is growing, with approvals in the EU and the US of our new epilepsy medicine.

    Looking a little further down the line, first results from the phase 3 program with our osteoporosis drug showed very promising results in reducing incidence of new vertebral fractures in postmenopausal women. Topline results of another study showed the compound is also effective in raising bone mineral density in men with osteoporosis.

    Further results are expected next year and we are encouraged by the potential of this product to improve the lives of women and men living with osteoporosis.

    This new molecule is not the only one with the potential to expand our portfolio. Our attractive early pipeline now encompasses nine different potential products. We will continue to invest in science, research and development to deliver future breakthrough solutions for patients.

    What does our 3 months interim report tell me? Well, it shows me we are on target for 2016 and off to our growth path – as expected. If you would like more details on any of the above or beyond, do not hesitate to get in touch Antje.Witte@ucb.com.

    Tags:
    Categories:
    Share:
  • Like

Leave a Comment